Dr. Reddy's Wins Tentative FDA Approval for Twice-Yearly HIV Prevention Injection
Bitget2026/11/02 14:35- Dr. Reddy's received tentative U.S. FDA approval under PEPFAR for twice-yearly injectable lenacapavir for HIV prevention.
- Pricing is set at US$ 40 per person annually across 120 countries outside the U.S. under Gilead's voluntary license.
- Initial supplies are expected by end-2026, with broader availability in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
